Charles Rudin, MD on KEYNOTE-604: How Does This Compare to Other Trials? #ASCO2020 @charlesrudin #ASCO @sloan_kettering

Charles Rudin, MD on KEYNOTE-604: How Does This Compare to Other Trials? #ASCO2020 @charlesrudin #ASCO @sloan_kettering

Cancer-News

1 month
9 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Charles Rudin, MD @charlesrudin of Memorial Sloan Kettering Cancer Center @sloan_kettering discusses KEYNOTE-604: pembrolizumab versus placebo plus etoposide and platnium as a first-line therapy in SCLC.
Up Next Autoplay